Validation of EGFR mutation testing on cytological smears of lung cancer using the Idylla platform

Pathology. 2022 Oct;54(6):810-814. doi: 10.1016/j.pathol.2021.10.006. Epub 2022 Jan 26.

Authors

Cameron Snell¹, Sam McManus², Kelly Robinson², Wendy Lewis², Samantha Arandelovic², Rohan Lourie², James Harraway²

Affiliations

¹ Mater Pathology, Mater Hospital Brisbane, South Brisbane, Qld, Australia; Cancer Pathology Research Group, Mater Research Institute, University of Queensland, Translational Research Institute, Brisbane, Qld, Australia. Electronic address: Cameron.snell@petermac.org.
² Mater Pathology, Mater Hospital Brisbane, South Brisbane, Qld, Australia.

PMID: 35090771
DOI: 10.1016/j.pathol.2021.10.006

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
DNA Mutational Analysis
ErbB Receptors / genetics
Humans
Lung Neoplasms* / diagnosis
Lung Neoplasms* / genetics
Mutation

Substances

EGFR protein, human
ErbB Receptors